Heath Damron | Co-founder and Chief Scientific Officer
Montani Biotechnologies, Inc

Day 3 - Thursday 2nd April @ 11:30

Panel: Genetic Adjuvants & mRNA Vaccine Durability: Next-Gen Strategies for Enhanced Immune Response

Introduction & Context:o    Challenges with mRNA vaccine durability and breadth o    Emerging role of genetic adjuvants o    Relevance to pandemic preparedness and immunological innovationTalk 1: Mechanisms & Promise of Genetic Adjuvantso    Overview of cytokine-encoded mRNA adjuvants o    IL-12 and other promising candidates o    Immunological mechanisms and delivery challengesTalk 2: Enhancing mRNA Vaccine Breadth & Durabilityo    Case studies on combining mRNA vaccines with genetic adjuvants o    Data on durability, breadth, and safety o    NIH funding landscape and regulatory considerationsTalk 3: Translational & Clinical Perspectiveso    Preclinical and early clinical data o    Formulation and delivery innovations o    Potential applications beyond infectious disease (e.g. allergy, autoimmunity)Discussion & Audience Q&Ao    Where do genetic adjuvants fit in the current vaccine tech landscape? o    Regulatory hurdles and funding gaps o    Opportunities for collaboration and future research 

Moderator: Jay Evans, Chief Scientific and Strategy Officer, Inimmune

×

Jay Evans / Panel: Genetic Adjuvants & mRNA Vaccine Durability: Next-Gen Strategies for Enhanced Immune Response

Jay Evans, Chief Scientific and Strategy Officer,
Inimmune

Jay Evans, Ph.D., is the Co-Founder and Chief Scientific & Strategy Officer (CSSO) of Inimmune Corporation (Missoula, MT) and Director of the Center for Translational Medicine at the University of Montana. Before joining the University of Montana, Dr. Evans spent 16 years with GSK...

CloseMore

David Dowling, Assistant Professor of Pediatrics, Harvard Medical School; Precision Vaccine Program, Division of Infectious Diseases, Boston Children's Hospital

×

David Dowling / Panel: Genetic Adjuvants & mRNA Vaccine Durability: Next-Gen Strategies for Enhanced Immune Response

David Dowling, Assistant Professor of Pediatrics, Harvard Medical School; Precision Vaccine Program, Division of Infectious Diseases,
Boston Children's Hospital

Using Adjuvant Science to shape the future of human health – The AIDD (Adjuvant Innovation, Discovery, and Development) Laboratory, led by Dr. David Dowling at Boston Children's Hospital and Harvard Medical School, pioneers adjuvant-centric approaches to enhance vaccine efficacy in vulnerable...

CloseMore

Heath Damron, Co-founder and Chief Scientific Officer, Montani Biotechnologies, Inc

×

Heath Damron / Panel: Genetic Adjuvants & mRNA Vaccine Durability: Next-Gen Strategies for Enhanced Immune Response

Heath Damron, Co-founder and Chief Scientific Officer,
Montani Biotechnologies, Inc

Heath Damron is Director of the Vaccine Development Center (VDC) at West Virginia University and Co-founder and Chief Scientific Officer of Montani Biotechnologies, Inc. He works in pre-clinical vaccine development, and the VDC collaborates with industry to evaluate experimental vaccines, including ...

CloseMore

Jonathan Kagan, Distinguished Scientist at Corner Therapeutics and Marian R. Neutra Professor of Pediatrics, Harvard Medical School